Randomized controlled trial comparing the effectiveness of tamsulosin, tamsulosin with tolterodine and double J stent position in controlling stent related symptoms after ureteroscopic lithotripsy

Christian A. Agbo; Guavar Nahar

doi:10.18203/2349-2902.isj20233918

Authors

Christian A. Agbo Department of Surgery, Benue State University, Makurdi, Nigeria
Guavar Nahar Department of Urology, Meenakshi Mission Hospital and Research Centre Madurai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2349-2902.isj20233918

Keywords:

USSQ, Stone, Tamsulosin, Tolterodine

Abstract

Background: Objective of the study was to determine the effect of stent position and medications in preventing stent-related symptoms.

Methods: This was a prospective study conducted at Meenakshi Mission Hospital and Research Centre Madurai, Tamil Nadu, India. 150 patients who underwent ureteroscopic lithotripsy with indwelling stent were distributed into three groups. On demand analgesics were given to group 1 (n=50), Tamsulosin 0.4 mg daily for group 2 (n=50) and tamsulosin 0.4 mg and tolterodine 4 mg daily for group 3 (n=50). The patients were also subclassified into appropriate or inappropriate group according to stent position. All patients completed various domains of Ureteral stent symptom questionnaire (USSQ) on 1st and 7th postoperative days. Appropriate tests statistics were performed using EPI-Info statistical software package.

Results: In control group, patients with appropriate stent position had significantly lower symptom scores than those with inappropriate stent position (p value~0.0001) in all domains of USSQ except global quality of life score (p value=0.08). Addition of tamsulosin 0.4 mg (group 2) had superadded beneficial effect in appropriate position group, but not in patients with inappropriately positioned stents. Patients taking both tamsulosin 0.4 mg and tolterodine 4 mg (group 3) had no significant improvement in symptom scores in appropriate position group (all domains of USSQ) and inappropriate position group (most domains).

Conclusions: Appropriate stent position is the most important independent factor than medications in preventing stent related symptoms; tamsulosin has superadded benefit in patients with correctly positioned stents.

Metrics

Metrics Loading ...

References

Zimskind PD, Fetter TR, Wilkerson JL. Clinical use of long-term indwelling silicone rubber ureteral splints inserted cistoscopically. J Urol. 1967;97:840-4.

Sighinolfi MC, Micali S, De Stefani S, Mofferdin A, Grande M, Giacometti M, et al. Indwelling ureteral stents and sexual health: a prospective, multivariate analysis. J Urol. 2007;178:229.

Irani J, Siquier J, Pirès C, Lefebvre O, Doré B, Aubert J. Symptom characteristics and the development of tolerance with time in patients with indwelling double-pigtail ureteric stents. BJU Int. 1999;84:276.

Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ. Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol. 2003;169:1065-9.

Ho CH, Chen SC, Chung SD. Determining the appropriate length of a double pigtail ureteral stent by both stent configurations and related symptoms. J Endourol. 2008;22:1427.

Damiano R, Autorino R, De Sio M Giacobbe A, Palumbo IM, D'Armiento M, et al. Effect of tamsulosin in preventing ureteral stent-related morbidity: a prospective study. J Endourol. 2008;22:651.

Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A prospective, randomized, double-blinded placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology. 2008;71:792.

Beiko DT, Watterson JD, Knudsen BE, Nott L, Pautler SE, Brock GB, et al. Double-blind randomized controlled trial assessing the safety and efficacy of intravesical agents for ureteral stent symptoms after extracorporeal shockwave lithotripsy. J Endourol. 2004;18:723.

Gupta M, Patel T, Xavier K, Maruffo F, Lehman D, Walsh R, et al. Prospective randomized evaluation of periureteral botulinum toxin type A injection for ureteral stent pain reduction. J Urol. 2010;183:598-602.

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM, et al. Is there a role for alpha1-blockers in treating Double-J stent-related symptoms? Urology. 2006;67:35.

Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol. 2003;169:1060-4.

Pilcher JM, Patel U. Choosing the correct length of ureteric stent: a formula based on the patient's height compared with direct ureteric measurement. Clin Radiol. 2002;57:59-62.

Park SC, Jung SW, Lee JW, Rim JS. The effects of tolterodine extended release and alfuzosin for the treatment of double-J stent-related symptoms. J Endourol. 2009;23:1913-7.

Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK, et al. Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013;41:247-52.

Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Varkarakis IM. Is there a role for alpha1-blockers in treating double-J stent-related symptoms? Urology. 2006;67:35-9.

Beddingfield R, Pedro RN, Hinck B, Kreidberg C, Feia K, Monga M. Alfuzosin to Relieve Ureteral Stent Discomfort: A Prospective, Randomized, Placebo Controlled Study. J Urol. 2009;181:170-6.

Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo IM, D'Armiento M. Effect of Tamsulosin in Preventing Ureteral Stent- Related Morbidity: A Prospective Study. J Endourol. 2008;22:651-5.

Norris RD, Sur RL, Springhart WP, Marguet CG, Mathias BJ, Pietrow PK, et al. A Prospective, Randomized, Double-blinded, placebo-controlled comparison of extended release oxybutynin versus phenazopyridine for the management of postoperative ureteral stent discomfort. Urology. 2008;71:792.

Lumiaho J, Heino A, Tunninen V, Ala-Opas M, Talja M, Välimaa T, et al. New bioabsorbable polylactide ureteral stent in the treatment of ureteral lesions: an experimental study. J Endourol. 1999;13:107-12.

Lee SJ, Yoo C, Oh CY, Lee YS, Cho ST, Lee SH, et al. Stent position is more important than α-blockers or anticholinergics for stent-related lower urinary tract symptoms after ureteroscopic ureterolithotomy: a prospective randomized study. Korean J Urol. 2010;51:636-41.